Analysts expect Translate Bio, Inc. (NASDAQ:TBIO) to report $-0.21 EPS on February, 14.After having $-0.97 EPS previously, Translate Bio, Inc.’s analysts see -78.35% EPS growth. The stock increased 0.70% or $0.04 during the last trading session, reaching $5.72. About 11,927 shares traded. Translate Bio, Inc. (NASDAQ:TBIO) has 0.00% since February 3, 2018 and is . It has by 0.00% the S&P500.

Southcross Energy Partners LP (SXE) investors sentiment decreased to 0.16 in Q3 2018. It’s down -0.54, from 0.7 in 2018Q2. The ratio fall, as 3 funds opened new or increased equity positions, while 19 sold and decreased their equity positions in Southcross Energy Partners LP. The funds in our database now hold: 1.07 million shares, down from 1.96 million shares in 2018Q2. Also, the number of funds holding Southcross Energy Partners LP in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 8 Increased: 0 New Position: 3.

The stock increased 0.26% or $0.0009 during the last trading session, reaching $0.3509. About 68,046 shares traded. Southcross Energy Partners, L.P. (SXE) has declined 74.16% since February 3, 2018 and is downtrending. It has underperformed by 74.16% the S&P500. Some Historical SXE News: 10/05/2018 – Southcross Energy 1Q Adjusted EBITDA $15.1M; 15/03/2018 Southcross Energy Partners, L.P. Announces Availability of the 2017 K-1 Tax Package; 27/03/2018 – SOUTHCROSS ENERGY PARTNERS – MERGER PROPOSAL PASSED WITH A VOTE OF MORE THAN 95 PERCENT OF VOTES CAST BY NON-AFFILIATED UNITHOLDERS; 27/03/2018 – SOUTHCROSS ENERGY HOLDERS APPROVE MERGER W/ AMERICAN MIDSTREAM; 27/03/2018 – Southcross Energy Partners, L.P. Unitholders Approve Merger With American Midstream Partners; 28/03/2018 – American Midstream Announces Southcross Unitholder Approval of Merger; 28/03/2018 – AMERICAN MIDSTREAM REPORTS SOUTHCROSS UNITHOLDER APPROVAL OF ME; 10/05/2018 – Southcross Energy 1Q Loss/Shr 21c; 27/03/2018 – Southcross Energy Sees Merger Closing in 2Q; 10/05/2018 – Southcross Energy 1Q Loss $16.8M

Southcross Energy Partners, L.P., together with its subsidiaries, provides natural gas gathering, processing, treating, compression, and transportation services in the United States. The company has market cap of $28.84 million. The firm also offers natural gas liquid fractionation and transportation services. It currently has negative earnings. In addition, it supplies natural gas to industrial, commercial, and power generation customers, as well as local distribution companies.

B. Riley Wealth Management Inc. holds 0% of its portfolio in Southcross Energy Partners, L.P. for 33,070 shares. Bank Of America Corp De owns 311,003 shares or 0% of their US portfolio. Moreover, Barclays Plc has 0% invested in the company for 102 shares. The California-based California Public Employees Retirement System has invested 0% in the stock. Creative Planning, a Kansas-based fund reported 141,404 shares.

More notable recent Southcross Energy Partners, L.P. (NYSE:SXE) news were published by: Globenewswire.com which released: “Southcross Energy Partners, L.P. Reports Third Quarter Results – GlobeNewswire” on November 14, 2018, also Seekingalpha.com with their article: “A Discounted Backdoor Into An 18% Yield – Buyout Should Close Very Soon – Seeking Alpha” published on June 23, 2018, Globenewswire.com published: “Southcross Energy Partners, L.P. Receives NYSE Continued Listing Standard Letter – GlobeNewswire” on August 31, 2018. More interesting news about Southcross Energy Partners, L.P. (NYSE:SXE) were released by: Seekingalpha.com and their article: “Southcross Energy: A Fixer Upper MLP In A Great Neighborhood – Seeking Alpha” published on November 08, 2018 as well as Globenewswire.com‘s news article titled: “Southcross Energy Partners, L.P. Terminates Merger with American Midstream Partners – GlobeNewswire” with publication date: July 30, 2018.

Among 2 analysts covering Translate Bio (NASDAQ:TBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Translate Bio had 2 analyst reports since November 14, 2018 according to SRatingsIntel. The stock has “Outperform” rating by Leerink Swann on Wednesday, November 14.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. The company has market cap of $258.21 million. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It currently has negative earnings. It has strategic alliances with Sanofi Pasteur.